» Articles » PMID: 39702901

Noninvasive Grading of Liver Fibrosis Based on Texture Analysis From MRI-Derived Radiomics

Abstract

Given the increasing global prevalence of metabolic syndrome, this study aimed to assess the potential of MRI-derived radiomics in noninvasively grading fibrosis. The study included 79 prospectively enrolled participants who had undergone MRE due to known or suspected liver disease between November 2022 and September 2023. Among them, 48 patients were diagnosed with histopathologically confirmed liver fibrosis. A total of 107 radiomic features per patient were extracted from MRI imaging. The dataset was then divided into training and test sets for model development and validation. Stepwise feature reduction was employed to identify the most relevant features and subsequently used to train a gradient-boosted tree model. The gradient-boosted tree model, trained on the training cohort with identified radiomic features to differentiate fibrosis grades, exhibited good performances, achieving AUC values from 0.997 to 0.998. In the independent test cohort of 24 patients, the radiomics model demonstrated AUC values ranging from 0.617 to 0.830, with the highest AUC of 0.830 (95% CI 0.520-0.830) for classifying fibrosis grade 2. Incorporating ADC values did not improve the model's performance. In conclusion, our study emphasizes the significant promise of using radiomics analysis on MRI images for noninvasively staging liver fibrosis. This method provides valuable insights into tissue characteristics and patterns, enabling a retrospective liver fibrosis severity assessment from nondedicated MRI scans.

Citing Articles

Impact of MRI Texture Analysis on Complication Rate in MRI-Guided Liver Biopsies.

Leonhardi J, Niebur M, Hohn A, Ebel S, Struck M, Tautenhahn H J Imaging Inform Med. 2025; .

PMID: 39934533 DOI: 10.1007/s10278-025-01439-0.

References
1.
El-Kassas M, Alswat K . Editorial: Emerging therapeutic approaches for non-alcoholic fatty liver disease. Front Med (Lausanne). 2024; 11:1437385. PMC: 11217539. DOI: 10.3389/fmed.2024.1437385. View

2.
Noureddin M, Lam J, Peterson M, Middleton M, Hamilton G, Le T . Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology. 2013; 58(6):1930-40. PMC: 4819962. DOI: 10.1002/hep.26455. View

3.
Younossi Z, Anstee Q, Marietti M, Hardy T, Henry L, Eslam M . Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2017; 15(1):11-20. DOI: 10.1038/nrgastro.2017.109. View

4.
Ge X, Zheng L, Wang M, Du Y, Jiang J . Prevalence trends in non-alcoholic fatty liver disease at the global, regional and national levels, 1990-2017: a population-based observational study. BMJ Open. 2020; 10(8):e036663. PMC: 7402189. DOI: 10.1136/bmjopen-2019-036663. View

5.
Petta S, Di Marco V, Pipitone R, Grimaudo S, Buscemi C, Craxi A . Prevalence and severity of nonalcoholic fatty liver disease by transient elastography: Genetic and metabolic risk factors in a general population. Liver Int. 2018; 38(11):2060-2068. DOI: 10.1111/liv.13743. View